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Abstract: Endocrine disrupting chemicals (EDC) are exogenous agents that alter
endogenous hormone signaling pathways. These chemicals target the neuroendocrine
system which is composed of organs throughout the body that work alongside the central
nervous system to regulate biological processes. Of primary importance is the
hypothalamic-pituitary-gonadal (HPG) axis which is vital for maintaining proper
reproductive function. Atrazine (2-chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine) is
a pre-emergent herbicide used to prevent the growth of weeds on various crops. This
herbicide is reported to widely contaminate potable water supplies everywhere it is applied.
As such, the European Union banned the use of atrazine in 2004. Currently the United States
Environmental Protection Agency regulates atrazine at 3 parts per billion (ppb; μg/L) in
drinking water, while the World Health Organization recently changed their drinking water
guideline to 100 ppb. Atrazine is implicated to be an EDC that alters reproductive
dysfunction by targeting the HPG axis. However, questions remain as to the human health
risks associated with atrazine exposure with studies reporting mixed results on the ability of
atrazine to alter the HPG axis. In this review, the current findings for atrazine’s effects
on the HPG axis are examined in mammalian, anuran, and fish models and in
epidemiological studies.
Keywords: atrazine; endocrine disrupting chemical; hormones; hypothalamus-pituitarygonadal axis; reproductive dysfunction
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1. Introduction
The endocrine system is comprised of numerous organs throughout the body that work in tandem
with the central nervous system (CNS) to regulate biological processes. Of primary importance is the
reproductive system which is regulated by the hypothalamic-pituitary-gonadal (HPG) axis. Briefly, the
HPG axis begins in the hypothalamus which serves as the integration center through the release of
gonadotropin releasing hormone (GnRH) into the hypophyseal portal system which stimulates the
synthesis and secretion of the gonadotropins (luteinizing hormone (LH) and follicle stimulating hormone
(FSH)) from the anterior pituitary gland [1]. In females, LH exerts its function on the ovaries to promote
ovulation and develop the corpus luteum; while FSH promotes follicular maturation and the synthesis
of ovarian estrogens [2]. In males, LH acts on Leydig cells to promote the synthesis and secretion of
testosterone, while FSH binds to Sertoli cells in order to promote spermatogenesis [3]. Additional
hormones including activin, inhibin, and follistatin help maintain the positive and negative feedback
systems required for gonadotropin homeostasis. Lastly, estradiol, progesterone, and testosterone
produced by the ovaries and testes regulate the positive and negative feedback loops for proper
reproductive function. A more in depth explanation of the HPG axis can be found in Vadakkadath and
Atwood [4].
Endocrine disrupting chemicals (EDCs) are exogenous agents that alter endogenous hormone
signaling pathways. Due to rapid industrialization, the production of these chemicals and their release
into the environment has grown dramatically. Therefore, public concern about the effects of EDCs on
human health has also increased substantially and heightened the need for further research into the
mechanistic effects of these compounds [5,6]. EDCs are diverse in structure and are present in many
products such as plasticizers, pharmaceuticals, and pesticides, allowing for a wide range of human
exposures. Epidemiological studies have focused on the association between EDC exposure and various
adverse health states, diseases, and disorders including reproductive dysfunction [7–10]. Although
progress is being made, further work is needed to understand the mechanisms behind the adverse health
outcomes associated with EDC exposure [6].
Uncovering the mechanisms of action behind the effects of EDCs on the reproductive system is of
key interest as reproduction and embryonic development are highly susceptible biological
processes [11]. Moreover, evidence suggests that exposure to EDCs can cause adverse effects not only
in organisms that come into contact with them, but also to future progeny of exposed
individuals [12–14]. Research investigating the mechanisms behind EDCs has focused on how EDCs
interact with hormone receptors of the nuclear receptor (NR) family. In mammals, NRs are involved in
numerous biological functions including fetal development, homeostasis, reproduction, metabolism, and
response to xenobiotic substances [6]. Primary hormone receptors that belong to this family are the
estrogen receptors (ER), androgen receptors (AR), and progesterone receptors (PR). However, thyroid
hormone receptors (TRs), retinoid X receptors (RXR), and peroxisome-proliferator-activated receptors
(PPAR) are also coming into the forefront. EDCs have the capability to directly bind to these receptors,
therefore eliciting agonistic or antagonistic effects. Some examples of EDCs that target NRs include
dichlorodiphenyltrichloroethane (DDT), polychlorinated biphenyls (PCBs), bisphenol A (BPA),
polybrominated biphenyls (PBB), and polycyclic aromatic hydrocarbons (PAHs).
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Numerous challenges are identified and need to be overcome when aiming to understand the
mechanisms of action of EDCs. First, is the variable persistence in the body and in the environment
which can range from a few days (e.g., bisphenol A (BPA)) to years (e.g., 1,1-dichloro-2,2-bis(pchlorophenyl) ethylene (DDE)) [15]. This variation in persistence can make linking EDC exposure to
adverse health outcomes a challenge. Additionally, the exposure period and duration can lead to
significant adverse effects specifically during the critical in utero or developmental periods [5]. Further
complicating our understanding of how EDCs disrupt hormonal homeostasis is their lack of a traditional
dose response, often exhibiting a non-monotonic dose curve which provides a challenge in defining
threshold levels. As such, during the 1990s EDCs became part of the “low dose hypothesis” indicating
that these compounds can have adverse effects at or below environmentally allowable levels especially
on reproduction and development [16].
Atrazine (2-chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine) is a pre-emergent herbicide used
to prevent the growth of broadleaf and grassy weeds on crops such as corn, sorghum grass, sugar cane,
and wheat [17–20] that is reported to have endocrine disrupting effects. The United States Environmental
Protection Agency (U.S. EPA) estimates approximately 76.5 million pounds of atrazine are applied
annually in the United States, making it one of the most widely used herbicides [21]. The U.S. EPA has
set the maximum contaminant level (MCL) for atrazine at 3 μg/L in drinking water supplies; however,
during spring and summer months, this level is often exceeded [17,18,22,23]. Due to the high solubility,
mobility in soil, long half-life, and widespread water contamination, atrazine was banned in the European
Union in 2004. Prior to this, Italy and Germany banned the use of atrazine in 1991 with Sweden, Finland,
and Denmark following suit in 1994 [24,25]. Alternatively, the World Health Organization (WHO)
recently revised the allowable level of atrazine in drinking water to 100 μg/L [26]. Today, atrazine is
still in use in more than 70 countries including Argentina, Brazil, China, and Mexico [25,27].
This article seeks to provide a comprehensive review of the new insights into atrazine exposure over
the last twenty years with a focus on providing a thorough investigation of reproductive dysfunction
elicited by atrazine exposure through the HPG axis in mammalian, anuran, and fish models and in
epidemiological studies. An online search through the NCBI database based upon atrazine exposure and
the HPG axis was assessed from 1995 through July 2015. Literature investigating the effects of atrazine
on the hypothalamus-pituitary-adrenal (HPA) and hypothalamus-pituitary-thyroid (HPT) axes, and
neurotransmitter studies were excluded.
2. The Effects of Atrazine on Female Reproductive Function in Mammalian Models
The primary focus of the endocrine disrupting properties of atrazine on the female HPG axis has been
at the forefront of investigation as reproduction and embryonic development are highly susceptible to
chemical insult. In the sections below, studies investigating the adverse effects of atrazine at various life
stages are discussed followed by the genetic and upstream cellular mechanisms behind the observed
morphological alterations in various female mammalian models (Table 1).
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Table 1. Reproductive effects of atrazine in female mammalian models.

Reference

Species

Exposure

Duration
In vitro

Pogrmic-Majkic et al. [28]

Rat granulosa cells

0 or 20 μM

48 h

Fa et al. [29]

Rat granulosa cells

0, 10, or 20 μM

12 or 48 h

Basini et al. [30]

Swine granulosa cells

0, 0.1, or 10 μM

48 h

0 or 10 μM

24 h

Increased estradiol and aromatase activity after 24 h in granulosa cells; Increased
estradiol and estrone in H295R cells; Increase in progesterone in both cell types

0, 1 nM, or 1 μM

24 h

Increase in aromatase activity in granulosa cell cultures; No alterations in aromatase
protein or proportion of cells expressing aromatase

0–30 μM

24 h

Increase in CYP19A1 activity; Increase in CYP19 mRNA

Tinfo et al. [31]
Holloway et al. [32]
Sanderson et al. [33]

Granulosa cells and
H295R adrenal cortical
carcinoma cells
Human granulosa and
endometrial stromal cells
H295R adrenal cortical
carcinoma cells

Outcomes
Increase in progesterone; Increase in progesterone/estradiol ratio; Increase in Star and
Cyp11a1; Activation of AKT and CREB
Increase in estradiol in 8-Br-cAMP stimulated granulosa cells; Decrease in Cyp11a1
and Lhr expression; Decrease in ovulatory gene expression (Areg, Ereg, PgR)
Decrease in estradiol at 0.1 μM; Increase in progesterone at 10 μM; Increase in
VEGF at 0.1 and 10 μM; Increase in NO at 10 μM

Gestational
Davis et al. [34]

Sprague-Dawley rats

0, 1, 5, 20, or 100 mg/kg/day

GD 14–21

Hovey et al. [35]

Long-Evans rats

0, 6.5, 50, or 100 mg/kg/day

GD 13–19

Rayner et al. [36]

Long-Evans rats

0 or 100 mg/kg/day

GD 13–15 or
15–17 or 17–19 or
13–19

Rayner et al. [37]

Long-Evans rats

0 or 100 mg/kg/day

GD 15–19

Ashby et al. [38]

AP and Sprague-Dawley
rats

0, 10, 30, or 100 mg/kg/day

Laws et al. [39]

Wistar rats

0, 12.5, 25, 50, 100,
or 200 mg/kg/day

Peripubertal
PND 21 up to
PND 46
PND 22- PND 41

Delay in vaginal opening at 100 mg/kg/day; No alterations in mammary gland
development on PND 45; No alterations in estrous cyclicity through PND 272
No effects on mammary gland development beyond a transitory response to high
doses at PND1
Delay in vaginal opening in the GD 13–15 treatment group; No alterations in estrous
cyclicity from PND 37–67; Decrease in area of mammary gland as soon as PND 4;
Delays in development of mammary glands through PND 67;
No alterations in serum hormone levels
Delay in age vaginal opening; Delays in mammary gland epithelial development; No
alterations in uterine or ovarian weight; No alterations in estrous cyclicity or serum
hormone levels
Decrease in uterine weight at 100 mg/kg/day at PND 30 and PND 33; Delay in age of
vaginal opening
Delay in VO in the 50, 100, and 200 mg/kg/day treatment groups; Decreases in
pituitary, ovary, uterine, adrenal, and kidney weight in 200 mg/kg/day at PND 41; No
alterations in T3, T4, or TSH; Alterations in estrous cycle in first 15 days following
VO at 100 mg/kg/day; No alterations in estrous cyclicity from PND 57–149
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Table 1. Cont.

Reference

Species

Exposure

Duration
Adult

Foradori et al. [40]

Sprague Dawley and
Long-Evans rats

0.75–100 mg/kg/day oral
gavage: 300–1460 ppm diet

4 days

Goldman et al. [41]

Long Evans rats

0, 10, 30, or 100 mg/kg/day

1 or 4 days

Foradori et al. [42]

Wistar rats

0, 50, 100, or 200 mg/kg/day

4 days

Quignot et al. [43]

Sprague-Dawley rats

0 or 200 mg/kg/day

14 days

Taketa et al. [44]

Sprague-Dawley rats

0 or 300 mg/kg/day

4 days or 2 weeks

Foradori et al. [45]

Wistar rats

0, 50, 100, or 200 mg/kg/day

4 days

Foradori et al. [46]

Wistar rats

0, 50, 100, or 200 mg/kg/day

4 days

Shibayama et al. [47]

Sprague-Dawley rats

0, 3, 30, or 300 mg/kg/day

2 or 4 weeks

Juliani et al. [48]

Wistar rats

0, 0.75, or 400 mg/kg/day

14 (0.75 mg/kg) or
30 days
(400 mg/kg)

McMullin et al. [49]

Sprague-Dawley rats

0, 30, 100, or 300 mg/kg/day

5 days

Cooper et al. [50]

Sprague-Dawley and
Long-Evans rats

0, 50, 100, 200,
or 300 mg/kg/day

1, 3, or 21 days

Outcomes
Decrease in LH surge and area under the curve in Sprague-Dawley rats treated by
oral gavage; Decrease in mean number of corpora lutea and number of ova in
Sprague-Dawley rats treated by oral gavage; No change with dietary consumption
Decrease in LH surge; Increase in serum progesterone; Increase
in Kiss1 mRNA expression
No alterations in gene expression, peptide levels, or immunoreactivity; Reduction
observed in GnRH pulse frequency; Increase in GnRH pulse amplitude
Decrease in uterine and ovary weight; Increase in estrone and estradiol; Increase in
ovarian aromatase expression; Increase in estrous cycle;
Alterations in steroidogenic genes
Abnormal estrus cycle (persistent diestrus); Luteal cell hypertrophy and atretic
follicles observed; Increase in serum progesterone;
Increase in steroidogenic gene SR-B1
Reduction in magnitude of LH and FSH surges; Decrease in GnRH neurons;
Measures of HPG activation return to normal 4 days after cessation
Decrease in LH pulse frequency and increase in pulse period and pulse amplitude in
200 mg/kg/day treatment group
Loss of corpora lutea; Increase in atretic follicles; Swelling of leuteal cells; Prolonged
estrous cycle; Decrease in ovarian and uterine weight
No increases in atretic antral follicles, but intensity level of apoptosis in granulosa
cells was visibly higher than control in the 0.75 mg/kg/day group; Disorganized
granulosa cells, discontinuous zona pellucida, high intensity of apoptosis in atretic
antral follicles in the 400 mg/kg/day treatment group
Decrease in LH at 30, 100, and 300 mg/kg/day;
No binding to estrogen receptor in vivo
Suppression of serum LH and PRL; Increase in pituitary LH

Abbreviations: AKT = Protein kinase B; CREB = cAMP response element-binding protein; FSH = Follicle stimulating hormone; GD = Gestational Day; GnRH = Gonadotropin releasing hormone;
HPG = Hypothalamus-pituitary-gonadal; LH = Luteinizing hormone; NO = Nitrous oxide; PND = Post-natal day; PRL = Prolactin; SR-B1 = Scavenger-receptor B1; TSH = Thyroid stimulating hormone;
T3 = Triiodothyronine; T4 = Tetraiodothyronine; VEGF = vascular endothelial growth factor; VO = Vaginal opening.
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2.1. Gestational Atrazine Exposure in Females
Studies examining the gestational effects of atrazine on female offspring have primarily focused
around mammary gland development and time of vaginal opening (VO). A study conducted by
Rayner et al., treated pregnant Long-Evans rats with 100 mg/kg/day atrazine from gestational day (GD)
15–19. Once pups were born, cross-fostering was used to determine if observable effects were
dam-mediated (gestational and lactational) or direct (gestational). Results indicated a significant delay
in VO in the litters which also received milk from atrazine exposed dams. Furthermore, offspring in all
treatment groups had delays in mammary epithelial development which was evident as early as postnatal
day (PND) 4 and continued to PND 40. Conclusions drawn from this study were that the delay in VO
was mediated through gestational and lactational atrazine exposure, while brief direct exposure in utero
caused the delay in mammary gland development [37]. A follow-up study was performed in order to
investigate whether the previously observed delay in mammary gland epithelium was dependent upon
particular developmental stages. This study exposed pregnant Long-Evans rats to the same atrazine
concentration (100 mg/kg/day); however, dosing periods ranged from GD 13–15, GD 15–17, GD 1–19,
or GD 13–19. These studies confirmed the atrazine induced delay in VO in the GD 13–15 treatment
group. Additionally, a delay in mammary gland development which began at PND 4 and continued
through PND 64 was confirmed, with GD 17–19 being the most sensitive developmental window [36].
In contrast to the aforementioned studies, two studies were conducted which found no alterations in
mammary gland epithelial development [34,35]. Discrepancies of these data sets have been hypothesized
to be due to technical variations between the studies. Hovey et al., excluded any whole mount tissue
samples that did not contain the entire ductal network; whereas the assumption was made that the studies
conducted by Rayner et al., did not evaluate the entire ductal system; therefore, compromising a
complete analysis [31,35–37]. Data from these studies provides evidence that atrazine may cause
alterations in mammary gland epithelial development; however, rigorous quantitative analysis should be
performed in future studies.
A controversial debate that circulates around atrazine is whether or not atrazine elicits mammary
gland tumor development. One study stated that a lifetime atrazine exposure (24 months) of 400 mg/L
caused an earlier onset of mammary gland tumor development in Sprague-Dawley (SD) rats [51].
Additional studies have been completed by Stevens et al., in Sprague-Dawley rats further supporting
that atrazine exposure increases the incidence of mammary gland tumor development [52,53]. However,
studies investigating incidence of tumor formation in Fischer-344 rats, did not find an increase in
mammary tumor formation [54,55]. A key biological difference causing this strain specific effect of
atrazine exposure is that Fischer-344 rodents maintain a normal estrous cycle throughout a greater
portion of its life cycle compared to Sprague-Dawley rats. Therefore, allowing reproductive senescence
to occur later in life [56]. In addition, it is well known that mammary tumor formation in rodents is
hormone dependent and is common among aging rats [57]. Moreover, it has also been recognized that
estradiol and prolactin can promote tumor growth. Eldridge et al., determined that atrazine does not have
estrogenic activity, but can alter the estrus cycle and increase estradiol; therefore, providing a hormonal
milieu conducive to tumor formation [58]. Data regarding mammary tumor formation due to atrazine
exposure appears to be trending towards the hypothesis that the development of mammary tumors is a
secondary outcome of the neuroendocrine alterations that arise from atrazine exposure.
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2.2. Peripubertal Atrazine Exposure in Females
As compared to peripubertal male studies (discussed in Section 3.2) fewer studies have aimed to
address the effects of peripubertal atrazine exposure on the HPG axis in females. Similarly to the
gestational studies, interest surrounding age of VO has been assessed along with estrous cyclicity as a
marker of successful reproductive function. A study conducted by Ashby et al., found that an atrazine
treatment of 100 mg/kg/day from PND 21 up to PND 45 caused a decrease in uterine weight at PND 30
and PND 33 along with an increase in age of VO [38]. Results from this study are in agreement with an
earlier study which showed that the same atrazine treatment (100 mg/kg/day) caused a delay in VO due
to exposure from PND 22–41. Further results from this study displayed altered estrous cyclicity during
the first 15 day interval following VO; however, the observational period in this study lasted through
PND 149 in which from PND 57–149, no alterations in estrous cyclicity were observed [39]. This
extended observational period is beneficial as only observing within the treatment period (PND 22–41)
does not allow for the naturally occurring irregularity in female estrous cycles that occurs at the onset of
puberty [39].
2.3. Adulthood Atrazine Exposure in Females
As previously mentioned, numerous neural mechanisms control the functioning of the HPG axis. The
key regulator of this pathway is the hypothalamus which provides the neural signals eliciting the release
of GnRH to act on the pituitary for the release of LH and FSH. Disruption of this neuroendocrine
pathway can lead to nonresponsive gonadotrophs and a loss of reproductive function and has been the
target of investigation for multiple studies. It has been shown that atrazine and its metabolites are
lipid soluble and can cross the blood brain barrier; therefore, allowing atrazine to interact with
GnRH neurons [59]. A study conducted by Foradori et al., exposed ovariectomized female Wistar rats
to 0, 50, 100, or 200 mg/kg/day for four days. Results from this study indicated that atrazine exposure
of 100 and 200 mg/kg/day reduced the numbers of activated GnRH neurons [45]. To complement this
data, an additional study was conducted which investigated the effects of atrazine directly on GnRH
pulsatile release, gene expression, and peptide levels [42]. Atrazine elicited a reduction in GnRH pulses
with higher pulse amplitude, confirming previous results [45]. In addition, no significant alterations were
observed in the expression of GnRH mRNA or in GnRH peptide levels. As previously discussed, GnRH
regulates the release of LH and atrazine has been reported to decrease LH pulse frequency and increase
pulse period and amplitude [40,46,49,50,57]. The results from Cooper et al., and Foradori et al., have
also demonstrated that atrazine does not affect the sensitivity of the pituitary to GnRH [46,50]. These
data combined with an additional study in which atrazine increased the concentration of GnRH in the
median eminence further implies that atrazine exerts its effects at the level of the hypothalamus and not
the pituitary [57]. The combined studies presented, contribute significant weight into the effects of
atrazine on the HPG axis through GnRH, LH, and FSH due to their strong experimental methodology.
Although progress has been made, it is still unknown whether atrazine directly affects GnRH neurons or
if it acts on one of the numerous neurotransmitter systems that can affect GnRH neurons [60–62].
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Another possible mechanism of the observed reduction in GnRH resides further upstream in the
hypothalamus. Kisspeptin neurons are located in the hypothalamic anteroventral periventricular nucleus
(AVPV) and directly innervate GnRH neurons; therefore, potentially attenuating the GnRH pulses
leading to the downstream reduction in LH [41,63,64]. Kisspeptin neurons also contain progesterone
and estrogen receptors, which could contribute to disruption in ovarian histology and reproductive
dysfunction. Although no studies have addressed whether or not atrazine directly affects kisspeptin
neurons, a study conducted by Goldman et al., observed an increase in Kiss1 mRNA following atrazine
exposure in female Long-Evans rodents [41]. This increase was observed only one day following
atrazine administration with no alterations present following a four day exposure. This increase is in
combination with an observed increase in progesterone (discussed below), further supporting that
immediate effects of atrazine exposure can alter additional upstream regulators of GnRH neurons.
Atrazine exposure has been shown to cause various histological alterations within ovarian tissue. A
study conducted by Shibayama et al., treated Sprague-Dawley rats with 0, 3, 30 or 300 mg/kg/day for
two to four weeks. Results from this study revealed a loss of corpora lutea, an increase in atretic follicles,
swelling of luteal cells, and a prolonged estrus cycle (hypothesized to be prolonged diestrus) in the
300 mg/kg atrazine treatment group [47]. Furthermore, female Wistar rats exposed to 0.75 or
400 mg/kg/day reported no alterations in atretic antral follicles, but a large amount of preantral follicles
presented disorganized granulosa cells and/or a degenerating oocyte. Ovotoxicity was also observed in
the antral follicles via high intensity of apoptosis in granulosa cells, nucleolus fragmentation of the
oocyte, and irregularities of the Zona Pellucida [48]. The ovotoxicity generated by atrazine occurred at
a relatively high dose of 400 mg/kg/day for 14 days. These data demonstrate that high doses can elicit
infertility and impair folliculogenesis. These data are in agreement with Laws et al. who report that
atrazine at levels of 200 mg/kg can alter estrus cyclicity [39]. One study conducted in female pigs
reported cystic ovarian degeneration and an increase in the persistence of the corpus luteum following
an atrazine exposure of 2 mg/kg in feed for 19 days [65]. This report is in agreement with rodent studies;
however there was a limited sample size. It has been identified that damage to antral follicles may lead
to changes in hormone levels and/or estrus cyclicity [66], all of which have been observed in various
rodent studies. These combined results suggest ovotoxicity and anovulatory effects of atrazine.
Progesterone (P4) is a key hormone that is needed for proper reproductive function, primarily in early
luteinization and is known to be secreted from both the ovaries and adrenal glands [41]. An increase in
progesterone levels due to atrazine exposure has been observed in pre-ovulatory granulosa cells and
H295R adrenal cortical carcinoma cells [31]. In addition, in vivo studies have reported increases in
progesterone following atrazine administration [41,44,67]. To further strengthen the disruption of
ovarian function, a study utilizing female pigs reported an increase in serum P4 and a decrease in
estradiol before the onset of estrus following dietary atrazine exposure [65]. These studies suggest that
this elevation of progesterone during the transitional period from the immature to the pre-ovulatory stage
demonstrates that atrazine alters ovarian function [28]. An additional mechanism behind the observed
increase in progesterone following atrazine exposure is the reported decrease in the expression of
luteinizing hormone receptors (LHR) in granulosa cells (discussed in Section 2.5). This decrease in LHR
can elicit a decrease in LH and in estradiol functions in the ovary including the development of the
corpora lutea, size of ovaries, and estrus cyclicity. As such, a synergistic relationship exists between LH
and P4; as P4 increases (and remains elevated) it can adversely affect negative feedback loops of the
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HPG axis causing a continual decrease in LH. Furthermore, research has shown that higher levels of P4
inhibit follicle development and can potentiate follicular atresia [68]. Therefore, the observed increase
in P4 could be contributing to the continued inhibition of the pre-ovulatory surge of LH leading to the
histological and reproductive alterations observed in females.
Estradiol and testosterone are also key steroid hormones involved in proper reproductive function.
Levels of these hormones are not as abundantly studied in female rodent models as compared to male
models (discussed in Section 3.3). A study conducted by Quignot et al., treated Sprague-Dawley rats
with 200 mg/kg/day atrazine for 14 days observed a decrease in ovarian testosterone; however, no
significant alterations were observed in plasma or ovarian estradiol [43]. A second study also observed
no alterations in serum estradiol following an atrazine exposure of up to 100 mg/kg/day in Long-Evans
rodents [41]. In vitro studies utilizing swine granulosa cells exposed to 0.1 μM atrazine for 48 h displayed
a decrease in estradiol, while no alterations occurred at 10 μM [30]. A second study conducted by
Fa et al., reported that atrazine inhibits estradiol production in FSH stimulated granulosa cells at 20 μM.
While in contrast, cAMP stimulated cells display an increase in estradiol following the same atrazine
exposure [29]. These differences could be attributed to cell type as well as treatment periods.
2.4. Cellular and Genetic Mechanisms of Reproductive Dysfunction in Females
The mechanism responsible for the conversion of testosterone to estrogen is aromatase (CYP19A1).
The effects of atrazine on CYP19A1 are controversial (as discussed below). In vitro literature utilizing
granulosa cells and adrenal cortical carcinoma (H295R) cells show that atrazine exposure increases
aromatase and aromatase activity [32,33]. This increase in activity should account for increases in
estradiol; however, as previously discussed, an increase in estradiol is not always observed [30,41,43].
Further mechanistic work was performed in order to understand the genetic components behind the
observed gonadal histology and hormonal alterations. Rat granulosa cells treated with various
concentrations of atrazine for 48 h found that atrazine exposure decreased luteinizing hormone receptor
(Lhr) mRNA expression and the expression of ovulatory genes amphiregulin (Areg), epiregulin (Ereg),
and progesterone receptor (PgR) [29]. Decreased expression of the ovulatory genes could be a
contributing factor to the increase in atretic follicles and cystic ovarian degeneration [47,48,59]. An
upstream regulator of LH function is the ERK1/2 pathway [69]. Although atrazine does not directly
affect the phosphorylation of ERK1/2, the activation of this pathway is hypothesized to be critical
for the atrazine induced attenuation of Lhr mRNA expression [29]. A study conducted by
Pogrmic-Majkic et al., provided additional mechanistic data regarding the observed increases in
abnormal ovarian morphology and progesterone elicited by atrazine exposure [31,41,44,47,48,59,67].
Findings suggest that atrazine causes an increase in P4, the P4/E2 ratio, and overexpression of
luteal markers (Star and Cyp11a1) through the stimulation of the cAMP, AKT, ERK1/2, and
CREBPB-signaling pathways most likely through the inhibition of phosphodiesterase 4 (Pde4);
therefore promoting premature luteinization in rat granulosa cells [28,33,70,71] (Figure 1).
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Figure 1. Working conceptual model of steroidogenesis and upstream regulators associated
with atrazine exposure. This diagram represents the upstream cellular mechanisms (upstream
regulators are in blue) and steroidogenic genes (in red) that are reported to be altered by
atrazine exposure. All genes are included above as their human homologs.
2.5. Tissue Levels of Atrazine in Females
Few epidemiological studies have identified atrazine and/or its metabolites in the urine of agricultural
workers. Therefore, the majority of epidemiological studies are retrospective in linking water
concentrations of atrazine to reproductive dysfunction and birth defects (discussed in Section 5). Animal
studies aiming to address the distribution of atrazine in tissues are limited. A study conducted by
Fraites et al., investigated the distribution of atrazine and its metabolites in maternal, fetal, and neonatal
fluid and tissue samples following gestational and/or lactational exposure [72]. Pregnant
Sprague-Dawley dams were exposed to 5 or 25 mg/kg/day from GD 14–20 or GD 18–20. The exposed
dam had the highest levels of the atrazine metabolite diaminochlorotriazine (DACT) in the plasma,
adrenal, brain, and mammary tissues. Atrazine contributed to less than 1% of total chlorotriazines
identified in the plasma and brain. However, higher atrazine amounts were identified in the adrenal and
mammary tissues. [72]. In addition, gonadal levels of atrazine and its metabolites were investigated.
DACT was identifiable in ovarian tissue only at 25 mg/kg, while the 5 mg/kg treatment group reported
levels of DACT below the limit of quantitation [72]. The strength of this study comes from the dose
levels of 5 and 25 mg/kg, as the majority of rodent studies (as discussed in Sections 2.1–2.3) rely on
higher levels (≥100 mg/kg). These lower levels allow for a more translatable approach to
epidemiological studies (discussed in Section 5). A second study conducted by Quignot et al., exposed
female Sprague-Dawley rats to 200 mg/kg atrazine for 14 days and found an accumulation of atrazine
in ovarian tissue [73]. Results from these studies provide support for the reproductive dysfunction
elicited by atrazine exposure through multiple avenues. First, these studies clearly show that atrazine
and DACT are present in brain tissue. Second, the presence of atrazine in mammary tissue supports key
findings that show gestational and lactational exposure is detrimental to development [37]. In addition,
the identification of atrazine in the adrenals provides support that atrazine can also target additional
neuroendocrine pathways including the HPA axis. Although gonadal tissue requires intensive sample
preparation due to their complex biological matrix and high lipid content, these studies show that atrazine
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is present in ovarian tissue [73] and highlight that further work is needed to link ovarian atrazine levels
to observed histological, hormonal, and cellular alterations.
2.6. Conclusions
The effects of atrazine on the female mammalian HPG axis have shown numerous adverse impacts
from in vitro, gestational, peripubertal, and adulthood exposures. These alterations ranged from delays
in puberty, altered estrus cycles, atretic ovarian follicles, reduction in gonadotropins, and cellular and
genetic alterations. These studies provide support of atrazine as an EDC and its ability to elicit
reproductive dysfunction throughout multiple life stages (Figure 2). While questions still remain on
human health relevancy of doses at which these adverse effects are observed, results from these studies
begin to provide insight into the reproductive dysfunction observed in epidemiological studies.

Figure 2. Working conceptual model of atrazine toxicity on the hypothalamus-pituitarygonadal (HPG) axis across mammalian, anuran, and fish species. This diagram summarizes
the main common alterations observed with atrazine exposure on the HPG axis based upon
studies across multiple species and exposure paradigms. Atrazine exposure elicits an
increase in Kiss1 mRNA and a decrease in gonadotropin releasing hormone (GnRH) release
leading to a downstream reduction in luteinizing hormone (LH) and follicle stimulating
hormone (FSH) from the anterior pituitary. This reduction in gonadotropins elicits alterations
in testosterone, estrogen, and progesterone. In addition, histological and morphological
alterations in the ovaries and testes are observed and are ultimately dependent on time of
exposure and dose. (Green indicates increases, pink indicates reductions, and grey indicates
that both increases and reductions are reported. Histological and morphological effects in
males are indicated in purple, while alterations in females are in red; VO: vaginal opening).
3. The Effects of Atrazine on Male Reproductive Function in Mammalian Models
The primary focus of the endocrine disrupting effects of atrazine on the male reproductive system has
progressed over the years but is still under investigation. In the sections below, studies investigating the
adverse health outcomes at various life stages are discussed followed by the genetic and upstream
cellular mechanisms behind the observed morphological alterations in various mammalian models
(Table 2).
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Table 2. Reproductive effects of atrazine in male mammalian models.

Reference

Species

Exposure

Duration

Outcomes

In vitro
Forgacs et al. [74]
Kucka et al. [70]

BLTK1 Murine
Leydig cells
Sprague-Dawley anterior
pituitary and Leydig cells

1, 3, 10, 30, 100, 300,
or 600 μM

12, 24, or 48 h

10–50 μM

Various time points

Abarikwu et al. [75]

Wistar rat Leydig cells

Cytotoxic studies
0.5, 5, 10, 25, or 50
g/mL

Cytotoxic studies
24–72 h; Gene
expression studies 2 h
Gestational

Stanko et al. [76]

Long-Evans rats

100 mg/kg/day

GD 15–19

Rosenberg et al. [77]

Sprague-Dawley rats

0, 10, 50, 75,
or 100 mg/kg/day

GD14-Parturition

Increase in progesterone and testosterone;
Alterations in steroidogenic genes
Increase in cAMP and prolactin in pituitary cells;
Inhibition of PDE4 isoenzymes
Decrease in cell viability at 48 and 72 h at 25 and 50 μM;
Alterations in steroidogenic gene expression
No body weight alterations; Delay in preputial separation;
Increase in testosterone and decrease in estrone at PND 120;
Decrease in estradiol at PND 180
Increase in dead pups at 75 and 100 mg/kg; Increase in preputial
separation at 100 mg/kg/day; Decrease in angiogenital distance
at 100 mg/kg/day; No gross morphology alterations; Decrease in
serum and intratesticular testosterone

Peripubertal
50, 100,
or 200 mg/kg/day

Jin et al. [78]

ICR mice

3 weeks

Pogrmic-Majkic et al. [79]

Wistar rats

Pogrmic et al. [80]

Wistar rats

In vitro: 1–50 μM
In vivo: 200 mg/kg
50 or 200 mg/kg/day

Friedmann et al. [81]

Rat

50 mg/kg/day

Trentacoste et al. [82]

Sprague-Dawley rats

0, 100, or 200 mg/kg/day

PND 22–48

Stoker et al. [83]

Wistar rats

0, 12.5, 25, 50, 100,150,
or 200 mg/kg

PND 23–53

24 or 72 h
PND 23–50
PND 46–48 (acute);
PND 22–48 (chronic)

Decrease in body, testes, and liver weight; Decrease in
testosterone; Increase in estradiol; Decrease in expression of
steroidogenic genes
Transient increases in steroidogenic genes after 24 h exposure
followed by a decline
Decrease in steroidogenic genes and androgens
Decrease in serum and intratesticular testosterone
Delay in preputial separation; Decrease in serum LH and
testosterone; Decrease in intratesticular testosterone;
Decrease in organ weights
Decrease in seminal vesicle and prostate weight; No alterations
in testes weight; Delay in preputial separation;
No alterations in serum testosterone at PND 53
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Table 2. Cont.

Reference

Species

Exposure

Duration

Outcomes

Adult
Song et al. [84]

Sprague-Dawley rats

38.5, 77,
or 154 mg/kg/day

30 days

Jin et al., [85]

ICR mice

0, 100, or 200 mg/kg/day

4 × 1 week

Riffle et al. [86]

Wistar rats

0, 5, 25, 75,
200 mg/kg/day

3 Days

Abarikwu et al. [87]

Wistar rats

0, 120, or 200 mg/kg/day

7 or 16 Days

Victor-Costa et al. [88]

Wistar rat

50, 200,
or 300 mg/kg/day

7, 15, or 40 days

Decrease in spermatozoa number; Increase in spermatozoa
abnormality; Decrease in serum testosterone; Decrease in
expression of inhibin-B; Increase in FSH and LH
Decrease in testicular testosterone; Decrease in relative testes
weight at 200 mg/kg; Decrease in steroidogenic gene expression
Increase in serum progesterone in intact and castrated males at
25 and 200 mg/kg and 25, 75, and 200 mg/kg respectively;
Increase in serum corticosterone at 25, 75, and 200 mg/kg in
intact and castrated rats; Increase in testosterone and luteinizing
hormone in intact males at 25 mg/kg; Alterations in proteins
associated with testosterone production
Decrease in seminal vesicle and prostate weight
at 200 mg/kg/day; Decreased sperm number with increased
abnormal sperm at 120 and 200 mg/kg/day
Decreased body weight, increased testes and adrenal weight;
Decreased testosterone; Increased estradiol; Dilation of
seminiferous tubules; Testicular atrophy

Developmental Origins of Atrazine Toxicity

DeSesso et al. [89]

Wistar rats

0, 1, 5, 25,
or 125 mg/kg/day

GD 6–21 or PND 2–21

Fraites et al. [72]

Sprague-Dawley rats

0, 1, 5, 20,
or 100 mg/kg/day

GD 14–21

Rayner et al. [90]

Long-Evans rats

100 mg/kg/day

GD 15–19

No alterations in spermatid counts in testes, spermatozoa counts
in epididymides, or plasma testosterone levels at PND 70 or
PND 170; Increase in percentage of abnormal sperm on PND 70
at 125 mg/kg/day; PND exposure showed a reduction in absolute
testes and epididymis weights in the 125 mg/kg/day treatment
group on PND 70; No effect on plasma testosterone or sperm
morphology at PND 70 and PND 170
No alterations in testosterone production, timing of puberty,
play behavior, AGD, or male sex organ weights
at any atrazine treatment at PND 59
Delay in preputial separation; Increase in lateral prostate weight
at PND 120; No alterations in testes and seminal vesicle weight
at PND 120 and PND 220; No alterations in serum testosterone
and androstenedione, but a decrease in prolactin at PND 220

Abbreviations: AGD = Angiogenital distance; cAMP = 3′-5′-cyclic adenosine monophosphate; FSH = Follicle stimulating hormone; GD = Gestational day; LH = Luteinizing hormone;
PDE4 = Phosphodiesterase 4; PND = Post-natal day.
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3.1. Gestational Atrazine Exposure in Males
The first study of interest exposed pregnant Long-Evans rats to 100 mg/kg/day atrazine from
GD 15–19 and male offspring were assessed at PND 120 and PND 180. Results demonstrated that
gestational atrazine exposure caused a significant delay in preputial separation. In addition, no significant
differences in testes weights, seminal vesicle weights, or alterations in prostate morphology were
observed. Serum testosterone and estrone were increased at PND 120, while at PND 180 a decrease in
estradiol and estrone was observed [76]. A second study exposed pregnant Sprague-Dawley rats to
100 mg/kg/day atrazine from GD14-parturition and found that atrazine exposure elicited an increase in
the angiogenital distance (AGD) at PND 21 along with a delay in preputial separation. Further analysis
at PND 60 found no alterations in body, testes, seminal vesicle, or prostate weight, while a reduction in
serum and intratesticular testosterone was observed [77]. The results from these two studies are in
agreement regarding an increase in age of preputial separation and no alterations in accessory organ
weights; however, contradictory findings are present regarding the effect of atrazine on serum
testosterone levels. It is known that preputial separation is androgen dependent and normally occurs
when androgen levels are high. Results from Rosenberg et al., support this hypothesis; however, findings
of Stanko et al., are contradictory as they have a delay in preputial separation along with an increase in
testosterone. This could be due to the differences in assessment windows as there is a much longer
latency period in the Stanko et al., study [76,77].
3.2. Peripubertal Atrazine Exposure in Males
Peripubertal atrazine exposure in males has also been under investigation and poses fewer challenges
than gestational exposures. One study exposing male juvenile Sprague-Dawley rats to 50 mg/kg/day of
atrazine acutely from PND 46–48 or chronically from PND 22–48 showed a significant reduction in both
serum and intratesticular levels of testosterone in both treatment groups [81]. In a similar study in which
male Sprague-Dawley rats were exposed to 100 or 200 mg/kg/day atrazine from PND 22 also found a
delay in preputial separation, reduction in serum testosterone and luteinizing hormone along with
decreases in body, prostate, and seminal vesicle weight [82]. A third study was conducted that followed
a similar dosing regimen in which results revealed a significant decrease in body weight at 200 mg/kg
along with an increase in relative testes weight at 100 and 200 mg/kg. Regular testes weight was
decreased at 50 and 200 mg/kg. In addition, a significant decrease in serum testosterone was noted in all
atrazine concentrations, along with a corresponding increase in estradiol concentration in the 100 and
200 mg/kg treatment groups [78]. Lastly, a study exposing Wistar rodents from PND 23–53/54 found a
significant reduction in body weight, ventral prostate weight, and seminal vesicle weight, but no
alterations in testicular weight. Furthermore, a delay in preputial separation was once again
observed [83]. Overall the results from these studies support that peripubertal atrazine exposure elicits a
delay in preputial separation, decreases testosterone, and increases estradiol.
3.3. Adulthood Atrazine Exposure in Males
As previous studies have aimed to address the gestational and developmental aspects of atrazine
toxicity, it is of equal importance to address effects during adulthood. Adult male Wistar rodents
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(120 days old) were exposed to 50 (15 days), 200 (15 or 40 days), or 300 (7 days) mg/kg/day atrazine.
Results from this study demonstrated that atrazine exposure of 200 mg/kg for 15 days and 300 mg/kg
for 7 days caused a decrease in body weight and an initial increase in relative and absolute testes and
adrenal weight; while the 200 mg/kg dose for 40 days caused a reduction in relative and absolute testes
weight. Furthermore, a reduction in plasma testosterone was observed in all treatments except in the
50 mg/kg dose for 15 days. The treatment of 200 mg/kg for 15 days also increased plasma and testicular
estradiol. Testis morphology revealed atrazine exposure caused dilation of the seminiferous tubules at
200 mg/kg for 15 days and 300 mg/kg for 7 days. Leydig cells also showed alterations caused by atrazine
exposure including irregular nuclei with an increased amount of heterochromatin [88]. It is in agreement
throughout the literature that atrazine exposure decreases body weight [82,83,87]; however, alterations
in testes weight has been controversial [83,87]. The results from this study showed an initial increase in
testicular weight with shorter atrazine exposures, but observed a decrease with longer exposure periods.
The initial increase in testes weight corresponded with the observed larger lumen of seminiferous tubules
which could be caused by fluid accumulation, while the later reduction corresponded to the observed
increase in testicular atrophy [88].
An additional study addressing the hormonal and histological alterations caused by atrazine, exposed
adult male Sprague-Dawley rats to 38.5, 77, or 154 mg/kg/day for 30 days. Once dosing was complete,
testes were removed and analyzed. A decrease in testes weight was observed in the 154 mg/kg treatment
with no alterations in seminal vesicle, prostate, or epididymis weight. Histological results showed
irregular and disordered arrangement of seminiferous epithelium at 154 mg/kg along with a decrease in
the number of spermatozoa and an increase in spermatozoa abnormalities. A decrease in testicular
markers was also observed in the 74 and 154 mg/kg treatment groups including testicular acid
phosphatase (ACP), alkaline phosphatase (AKP), lactate dehydrogenase (LDH), and succinate
dehydrogenase (SDH). Regarding serum hormone levels, a decrease in testosterone was observed at
74 and 154 mg/kg along with an increase in LH and FSH [84]. Histological results of the testes tissue
revealed loose intercellular connections which could also disturb the junctions between Sertoli and germ
cells leading to a reduction in testosterone. This reduction in testosterone levels could be responsible for
the observed reduction in INH-B synthesis in the Sertoli cells. INH-B is a marker of Sertoli cell function
and spermatogenesis. Additionally, the secretion of FSH and LH is regulated by testosterone and
INH-B through a classic negative feedback loop. Therefore, atrazine exposure is hypothesized to damage
Leydig and Sertoli cells which then causes a decrease in INH-B from Sertoli cells and a decrease in
testosterone from Leydig cells. This decrease in testosterone would then cause an increase in LH and
FSH. However, the majority of studies (discussed in Section 2.3) indicate that atrazine decreases LH and
FSH which is contradictory to the results of this study. These inconsistent findings could be due to the
differences in treatment levels and/or exposure periods. An additional study showed that adult male
Wistar rats exposed to 120 or 200 mg/kg/day for 7 or 16 days showed a decrease in testicular sperm
count, epididymal sperm count, and sperm motility along with an increase in number of dead and
abnormal sperm [87]. It is well accepted that a decrease in sperm count combined with an increase in
sperm abnormalities can increase the risk of infertility. The association between atrazine exposure and
poor semen quality was also reported in an epidemiological study [91].
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Literature regarding atrazine and its effects on male steroidogenesis has focused on morphological,
hormonal, and proteome alterations in various rodent models. The hormone profiles and testes proteomes
of adult male Wistar rats were characterized following a 3 day atrazine exposure of 5, 25, 75, or
200 mg/kg/day. Results from this study showed a significant increase in progesterone and corticosterone
in the 25 and 200 mg/kg treatment groups. Additionally, an increase in luteinizing hormone and
testosterone was observed only at the 25 mg/kg treatment group. Proteomic analysis of testes tissue
revealed alterations in six proteins primarily correlated with testosterone. Although no steroidogenic
proteins were found to be altered in this study, the majority of the proteins were linked to ubiquitin-C
(UBC). UBC is a component of the ubiquitin-proteasome pathway which is part of the glucocorticoid
receptor degradation response. However, progesterone receptors are also targeted for degradation in the
same manner [86].
3.4. Developmental Origins of Atrazine Toxicity
Studies investigating the effects of early life exposure to environmental stressors or stimuli increased
dramatically over the past decade. These studies seek to investigate the developmental origins of health
and adult disease (DOHaD) hypothesis which states that exposure to stressors during sensitive times of
an organism’s life, specifically during developmental stages, can cause changes to the genome and
epigenome thereby resulting in an increased susceptibility to the development of health issues or diseases
later in life [91,92]. Further complicating the establishment of a link between exposure and a disease
state is the time that elapses between exposure and outward response or development of a
disease [92,93]. Thus, it may take years for an individual to present a disease or dysfunctional state [94].
A few studies have started to investigate atrazine toxicity using the DOHaD exposure paradigm with
rodent models. In one study, pregnant Long-Evans rats were exposed to 100 mg/kg/day atrazine from
GD 15–19. Later in life observations at PND 120 revealed an increase in lateral prostate weight and
inflammation in male offspring, but no alterations in serum testosterone, estrogen, or prolactin were
observed. By PND 220, increased prostate weight was still observed; however, inflammation was no
longer present. Furthermore, an increase in the weight of the anterior pituitary was observed. At this later
time point, a decrease in prolactin was observed. Results from this study showed that in utero exposure
combined with nursing from an atrazine treated dam enhanced the effects on prostate and pituitary
weight and prostate inflammation [90]. This study is in agreement with a previous study indicating lateral
prostate inflammation at PND 120 [95]. However, this could be a transient effect or require longer or
higher levels of atrazine exposure to continue inflammation as it was no longer present at PND 220.
Male offspring also had a delay in puberty (discussed in Sections 3.1–3.2); a stated hypothesis is that
the observed effects could be due to early hormonal alterations or early postnatal brain development,
especially in the area of the median eminence, which is critical for the timing of preputial
separation [90]. Furthermore, atrazine may effect factors in the median eminence that regulate LHRH
release, levels of ghrelin (a negative regulator of LH), or alterations in leptin [96].
A second study examining the later in life effects of a gestational atrazine exposure treated pregnant
Wistar rats from GD 6–21 with 1, 5, 25, or 125 mg/kg/day atrazine with evaluation of male offspring at
PND 70 and PND 170. Results indicated a decrease in pituitary weight in the 125 mg/kg/day treatment
group at PND 70. While analysis of testes tissue revealed no alterations in spermatid counts in testes or
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spermatozoa counts in the epididymides at PND 70 and 170, an increase in the number of abnormal
sperm was significantly increased in the 125 mg/kg/day treatment group at PND 70 and in the
25 mg/kg/day treatment group on PND 170. Plasma testosterone levels were also unaffected at PND 70
or 170 [89]. In addition, lactational exposure in offspring from PND 4-PND 21 had a reduction in
absolute testes and epididymis weights at PND 70. Evaluation at PND 170 showed a reduction in testes
weight and abnormal sperm in the 125 mg/kg/day treatment group. No alterations in plasma testosterone
levels were observed at any time point or dose [89]. Results from this study showed that atrazine had a
minimal effect on male reproductive endpoints. This study is in contrast to the previously mentioned
study [82] in which peripubertal atrazine exposure caused a reduction in plasma and intratesticular
testosterone as well as reductions in seminal vesicle and prostate weights. These differences may be
contributed to the differences in dosing and observational periods. In contrast to the previously
mentioned studies, one study was conducted that utilized a similar experimental design in which
pregnant female Sprague-Dawley rats were exposed to 1, 5, 20, or 100 mg/kg atrazine from GD 14–21.
Analysis of male offspring exposed in utero to 1–20 mg/kg/day did not have altered testosterone
production, timing of puberty, or play behavior [72].
3.5. Cellular and Genetic Mechanisms of Reproductive Dysfunction in Males
Steroidogenesis in males occurs in Leydig cells and is primarily mediated through the interaction of
LH with the luteinizing hormone receptor (LHR). Steroidogenesis is mediated through multiple
signaling pathways, including cAMP dependent regulatory events [70,74,79,80,97,98]. Numerous genes
are involved in steroidogenesis and are under investigation in order to define the genetic mechanisms
behind the observed reproductive dysfunction (Figure 1).
Pogrmic et al., obtained Leydig cells from peripubertal rats that were treated with 50 or
200 mg/kg/day from PND 23–50. Extracellular levels of cAMP along with mRNA transcripts of
luteinizing hormone receptor (Lhr), scavenger receptor B-1 (Sr-b1), steroidogenic factor-1 (Sf-1),
steroidogenic acute regulatory protein (Star), 3β-hydroxysteroid dehydrogenase (Hsd), Cyp17a1,
translocator protein (Tspo) and 17β-Hsd were assessed. Results report that atrazine decreased cAMP,
and the expression of Lhr, Sr-b1, Star, Sf-1, Pdeb4, Cyp17a1, Tspo, and 17β-Hsd. This strong inhibition
of steroidogenic genes and cAMP are mechanistic of the observed decrease in androgen production. It
has been identified that the cAMP/PKA pathway is an upstream regulator of numerous steroidogenic
genes and results from this study confirm this relationship. Furthermore, atrazine did not have an effect
on the expression of 3β-Hsd. This provides evidence that atrazine does not affect the conversion of
pregnenolone to progesterone [80]. A second study conducted by the same group used short term atrazine
exposure of 24 h in peripubertal rats (PND 51). Contrary to the previous study [80], an acute 24 h atrazine
exposure elicited an up regulation of cAMP signaling and increased expression of steroidogenic genes
(Sf-1, Star, 17β-Hsd, Cyp17a1) in Leydig cells. Confirmation by in vivo studies also demonstrated a
stimulatory effect of atrazine on cAMP signaling and steroidogenesis [79]. These two studies combined
suggest that atrazine has the potential to elicit a biphasic response through stimulatory actions following
acute exposure, while chronic atrazine exposure elicits strong steroidogenic inhibition [79].
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As previously stated cAMP plays a strong regulatory role and can elicit a robust increase in
steroidogenesis. Key inhibitors of cAMP are phosphodiesterases (PDEs) which cause a decrease in the
conversion of cAMP to 5′-AMP [70,71]. Atrazine has been identified as an inhibitor of PDEs; therefore,
providing a means of the observed increase in cAMP following acute atrazine exposure [70]. A
transcriptomic analysis of BLTK1 murine Leydig cells revealed an up regulation of Pde10, Pde4b, and
Pde4dip in response to a 48 h atrazine exposure [74]. This upregulation of PDEs could be a compensatory
response as a means to decrease cAMP levels; which previously were shown to be increased following
short term atrazine exposure [70].
3.6. Tissue Levels of Atrazine in Males
As previously stated, studies examining tissue distribution in animal models is currently limited,
especially in regards to male models. Thus far, a study conducted by Ross et al., exposed male C57BL/6
mice to a single dose of 5, 25, 125, or 250 mg/kg atrazine and measured atrazine and metabolite levels
in urine, plasma, and various tissues (liver, kidney, brain, spleen, and thymus). Urine analysis reported
a dose dependent increase in atrazine and its metabolites with the highest concentration occurring in
DACT which was two orders of magnitude higher than atrazine, 24 h after exposure. Atrazine and DACT
were also identified in the plasma, brain, liver, kidney, spleen, and thymus tissue [99]. Although this
study demonstrates that atrazine is taken up into numerous tissues, its weakness lies in the absence of
testes analysis. As steroidogenesis occurs within the gonads, understanding how much atrazine was
taken up and how quickly it is eliminated may aid in the understanding of the morphological, hormonal,
and cellular mechanisms of atrazine toxicity. A study conducted by Fraites et al., exposed pregnant
Sprague-Dawley dams to 5 or 25 mg/kg/day from GD 14–20 or GD 18–20. Analysis of the male fetus
(GD 20) reported a dose-dependent increase in atrazine. The male offspring (PND 10) reported high
levels of DACT in the plasma while the brain contained lower and more variable levels of atrazine.
Testes analysis displayed a dose-related increase in DACT between the 5 and 25 mg/kg treatment
group [72]. While analysis regarding atrazine accumulation in the testes is limited, this data is a stepping
stone in linking gestational atrazine exposure to previously observed morphological alterations [76,77].
3.7. Conclusions
Overall literature regarding the effects of atrazine on the mammalian male reproductive system report
congruent findings that support the hypothesis that atrazine adversely affects the HPG axis contributing
to reproductive dysfunction, but questions still remain regarding the later-in-life effects and exposure to
lower atrazine doses.
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4. The Effects of Atrazine on Reproductive Function in Anuran and Fish Models
4.1. The Effects of Atrazine on Reproductive Function in Anuran Models
Studies utilizing Xenopus laevis for examining atrazine toxicity have been under investigation for
many years and have used various exposure periods and concentrations (Table 3). In a series of studies
by Hayes et al., atrazine exposures of 0.1–200 μg/L were reported to elicit hermaphroditism, decreases
in testosterone, decreases in testosterone dependent morphogenesis, and decreased mating
competition [100–102]. While a separate study found that atrazine at 100, 450, and 800 μg/L delayed
metamorphosis of X. laevis [103]. Additional developmental studies with X. laevis report contrasting
results in which exposures ranging from 0.1 to 100 μg/L did not elicit alterations in growth or
larval development, sex ratios, or gonadal histology [104–109]. Other species of frogs have also been
used to examine atrazine toxicity; however, similar to the X. laevis studies, conflicting results are
reported [103,110,111].
Studies aiming to address atrazine toxicity with adult X. laevis show minimal alterations. A recent
study exposed adult X. laevis to 100 μg/L atrazine for 120 days. The results obtained from this study
were a delay in growth, but no hermaphroditism was reported in males. This exposure regime also caused
a delay or prevented the development of seminiferous tubules along with proteomic significance in
proteins associated with tight junctions and apoptosis [112]. An additional adult study with exposures
from 1 to 250 μg/L also report no alterations in gonadosomatic index (GSI), germ cell morphology, or
alterations in estradiol concentrations [113]. Although there are contrasting reports regarding the toxicity
to X. laevis, it is important to take into consideration atrazine concentrations and exposure periods for
future assessment.
4.2. The Effects of Atrazine on Reproductive Function in Fish Models
Various fish species have also been used to investigate the adverse effects of atrazine exposure. As
previously stated, in utero and developmental periods are susceptible to chemical insults and have the
potential to alter the genetic profile of developing organisms. A developmental study in which zebrafish
embryos were exposed to 0, 0.3, 3, or 30 μg/L atrazine revealed a significant increase in head length
following an embryonic atrazine treatment through 72 h post fertilization (hpf). Furthermore, the
transcriptomic profile identified gene alterations associated with neuroendocrine and reproductive
function, cell cycle, and carcinogenesis [114]. As the majority of studies focus on morphological
alterations during developmental exposures, this study was unique in providing a genetic profile that
could be connected to physiological changes and responses as a result of the developmental atrazine
exposure [114].
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Table 3. Reproductive effects of atrazine in anuran and fish models.

Reference

Exposure (μg/L)

Chen et al. [109]

0 or 100

Hayes et al. [102]

0 or 2.5

Kloas et al. [107]

0, 0.01, 0.1, 1, 25, or 100

DuPreez et al. [106]

0, 1, 10, or 25

Oka et al. [108]

0, 0.1, 1, 10, or 100

Hayes et al. [101]

0, 0.1, 0.4, 0.8, 1, or 25

Coady et al. [105]

0, 0.1, 1, 10, or 25

Hecker et al. [112]

0, 10, or 100

Hecker et al. [113]

0, 1, 25, or 250

Freeman et al. [103]
Carr et al. [104]

0, 100, 450, or 800
0, 1, 10, or 25

Hayes et al. [100]

0, 0.1–200

Hayes et al. [110]

0, 0.1, or 25

Spolyarich et al. [111]

0, 0.1, 1, 3, or 30

Duration

Outcomes

African Clawed Frog (Xenopus laevis)
No signs of hermaphroditism; Delay of seminiferous tubules; Alterations in 143
Stage 46/47-120 days
and 121 proteins in testes and ovaries, respectively; Proteins involved in cellular
and metabolic processes along with apoptosis and tight junctions were altered
Decrease in plasma testosterone; Decrease in size of dermal breeding glands;
Decrease in relative number of testicular tubules with mature sperm bundles
Hatching-Metamorphosis (stage 66)
which disappeared 3 years after metamorphosis;
Decrease in mating competition
No effect on growth or larval development;
8 dpf–metamorphosis (83 dpf)
No effects observed on sex ratios or on gonadal histology
No effect of clutch size, hatching rate, or time to metamorphosis in F1
96 hpf–2 ypm
generation; No alterations in sex ratio of offspring (F2); No alterations in
testicular morphology (F1 or F2)
Tadpole (stage 49)–metamorphosis
No effect on metamorphosis, gonad development,
(stage 66)
or aromatase expression; No alterations in levels of vitellogenin
Larvae-stage 66
Gonadal malformations; Increase in number of hermaphrodites
Concentrations of 0.1 and 25 μg/L did not alter mortality, metamorphosis,
72 hph-2-3 mpm
gonad development, or aromatase activity; 1 μg/L elicited a decrease in estradiol
No alterations in germ cell development, aromatase,
49 days (Adult)
or plasma hormone concentrations
No alterations in testicular aromatase activity, expression of cyp19,
36 days (Adult)
gonadosomatic index, or plasma estradiol;
A significant decrease in plasma testosterone was observed at 250 μg/L
Stage 47 or 54–1, 2, 3, 4, or 5 weeks
Delayed metamorphosis at 100, 450, and 800 μg/L
48 hph–metamorphosis (stage 66)
No alterations in mortality, larval growth, metamorphosis, or sex ratios
Hatching (stage 48)–trail reabsorption
Hermaphroditism in males; Decrease in testosterone levels at 25 μg/L
(stage 66)
Leopard Frog (Rana pipiens)
2 dph–tail reabsorption (stage 66)
Underdeveloped testes; Sex reversal in some males (testicular oocytes observed)
Spotted Marsh Frog (Limnodynastes tasmaniensis)
No alterations in tadpole growth, development, or sex ratios; Testicular oocytes
Gosner stage 28–44
observed in one fish at 3 μg/L atrazine, although not statistically significant
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Table 3. Cont.

Reference

Exposure (μg/L)

Tillitt et al. [115]

0, 0.5, 5, or 50

Battelle [116]

0, 25, or 250

Bringolf et al. [117]

0, 5, or 50

Nadzialek et al. [118]

0, 100, or 1000

Spanòet al. [119]

0, 100, or 1000

Papoulias et al. [120]

0, 0.5, 5, or 50

Shenoy [121]

0, 1, or 13.5

Shenoy [122]

0, 1, or 15

Kroon et al. [123]

0, 0.1, 0.5, 5, 50, or 100

Duration

Outcomes

Fathead Minnow (Pimephales promelas)
Decrease in total egg production; Reduction in total number of
spawning events; No alterations in steroid hormone levels;
Adult exposure (14 or 30 days)
Testicular oocytes found in the 5 μg/Ltreatment group;
Ovaries with lipid accumulation and atretic follicles observed
No alterations in GSI, mean egg production or spawning events; No histological
Adult exposure (21 days)
alterations (no atretic follicles; testicular atrophy)
No alterations in survival, spawning, egg production,
Adult exposure (21 days)
relative gonad weight, or in gonad histology
Goldfish (Carassius auratus)
No alterations in GSI, plasma concentrations of estradiol, or alterations in
Adult exposure (56 days)
cyp19a1; Decrease in 11-ketotestosterone after 56 day
exposure in the 1000 μg/L treatment
No alterations in GSI; Decrease in testosterone and 11-ketotestosterone and an
increase in estradiol in the 1000 μg/L treatment group; Structural disruption in
Adult exposure (21 days)
testis tissue (1000 μg/L); Follicular atresia in ovary tissue
in both treatments; No changes in vitellogenin
Japanese Medaka (Oryzias latipes)
Decrease in total egg production in all atrazine treatments after day 25 of
Adult (14 or 38 days)
exposure; No alterations in spawning events, GSI, aromatase protein, or whole
body estradiol or testosterone
Guppies (Poecilia reticulate)
Atrazine exposed male offspring were less likely to perform mating behaviors
Adult (through gestation)
(frequency of gonopodium swings and number of forced copulatory events), and
performed less frequently than control male
No change in number of mating attempts; Decrease in number of mating
Adult male (16 weeks)
displays; Decrease in number of orange spots
Barramundi (Lates calcarifer)
No alterations in cyp19b1 in brain tissue; No alterations in VGT; Increase in
Juvenile (48 h)
plasma testosterone at 0.1 and 5 μg/L; Increase in plasma estradiol at 5 ppb
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Table 3. Cont.

Reference

Exposure (μg/L)

Duration

Outcomes

Zebrafish (Danio rerio)
Freeman et al. [124]

0, 0.3, 3, or 30

1–72 hpf

Wirbisky et al. [125]

0, 0.3, 3, or 30

1–72 hpf

Weber et al. [114]

0, 0.3, 3, or 30

1–72 hpf

Corvi et al. [126]

0, 0.1, 1, or 10 μM

17 dpf–130 dpf

Suzawa and Ingraham [127]

0, 0.1, 1, or 10 μM

17 dpf–6 mpf

Kazeto et al. [128]

4.6, 46, or 460 nM

17 dpf–20 dpf

Decrease in spawning events at 30 μg/L treatment; Egg bound and increase in
atretic follicles in adult females exposed to 30 μg/L; Increase in ovarian
progesterone in adult females exposed to 3 or 30 μg/L; Transcriptomic analysis
revealed alterations in genes involved in steroidogenesis in adult female ovary
Decrease in serotonin metabolite 5-hydroxyindoleacetic acid and serotonin
turnover in adult female brain; Transcriptomic analysis revealed alterations in
genes throughout the serotonergic pathway in adult female brain
Significant increase in head length at 72 hpf in all atrazine treatments;
Transcriptomic data included genes altered in neuroendocrine and reproductive
system function, cell cycle, and carcinogenesis
No alterations in sex ratio; No alterations in gonad development
Increase in expression of cyp19a1 in all concentrations; Skewed sex ratio
(increased number of females); Activation of MAPK pathway, SF-1, and PI3K
pathway; Phosphorylation of Akt/PKB; Increase in cAMP in JEG3 cells;
Upregulation in StAR and cyp11a1
No alterations in cyp19a1 or cyp19a2 at 4.6, 4.6, or 460 nM atrazine

Abbreviations: dpf = days post fertilization; dph = days post hatch; GSI = gonadosomatic index; hph = hours post hatch; mpm = months post metamorphosis; ppb = parts per billion (μg/L);
VGT = vitellogenin; ypm = years post metamorphosis.
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Multiple studies have been conducted to assess the effect of atrazine on the HPG axis in adult fish.
Initial studies assessing proper reproductive function have evaluated body and testes weight, GSI, mean
egg production, spawning events, and breeding behavior. A study which exposed fathead minnows to 0,
0.5, 5, or 50 μg/L during adulthood found that atrazine exposure decreased mean egg production and
spawning events in all atrazine treatments [115]. In an additional study by the same group using Japanese
medaka, a decrease in mean egg production was also observed at 0.5, 5, and 50 μg/L; however, no
decreases in spawning events occurred [120]. Furthermore, a study exposing zebrafish embryos to
atrazine concentrations of 0, 0.3, 3, or 30 μg/L from 1 to 72 hpf (only through embryogenesis) also
displayed a decrease in spawning events; however, no decrease in mean egg production was
observed [124]. Two contrasting studies have been reported in which no alterations in mean egg
production or spawning events occurred in fathead minnows exposed to atrazine for 21 days. Battelle
administered an atrazine treatment of 25 or 250 μg/L [116]; while Bringolf et al., utilized an atrazine
treatment of 5 or 50 μg/L [117]. One difference that may account for the discrepancy is the use of a
flow-through system verses a static-renewal system. This could potentially alter atrazine uptake and
kinetics in the fish. A second contributing factor could be the difference in exposure periods. The studies
conducted by Battelle and Bringolf et al., followed the test exposure period of 21 days as prescribed by
the U.S. EPA [116,117], whereas a 38 day exposure period as used by Tillitt et al., and Papoulias et al.,
encompass a larger percent of the spawning period and may explain differences in findings [115,120].
Reductions in spawning events could be attributed to either a male or female specific effect on
reproductive behavior. Although direct breeding behavior was not assessed in these studies, previous
studies note alterations in reproductive behavior in various fish species [121,122,129]. Furthermore,
histological alterations within gonad tissue can also contribute to the lack of spawning events. In females,
atrazine was shown to cause an increase in atretic follicles [115,119,124]. The alterations in ovary
histology have also been observed in pig and rodent models as previously discussed [47,48,59].
Histological analysis of male testes tissue in anuran and fish species has not revealed significant
alterations as compared to adult rodent studies [84,88]. A few studies do report the occurrence
of testicular oocytes [115,126]; however, the prevalence of this event is rare and was not
statistically significant.
As the proper functioning of the neuroendocrine system is dependent upon hormonal regulation;
numerous hormones have also been analyzed in various fish models in order to complement rodent
studies. As previously discussed in rodent models, atrazine was shown to decrease GnRH, LH, FSH, and
T, while increasing E2, P4, and PRL. In aquatic species, one of the major differences within the
neuroendocrine system is that fish require 11-ketotestosterone as their main form of testosterone. A study
conducted by Spanò et al., reported an adult exposure of 21 days to 0, 100, or 1000 μg/L caused an
increase in plasma estradiol with corresponding decreases in 11-ketotestosterone and testosterone [119].
A second study with the same atrazine concentrations, but with a 56 day exposure found no alterations
in estradiol, but a significant decrease in testosterone in the 1000 μg/L treatment group [118].
Meanwhile, no alterations in steroid hormone concentrations after exposure to 0, 0.5, 5, or 50 μg/L
atrazine in Japanese medaka were observed [118]. A study conducted with juvenile barramundi observed
a non-linear dose response with an increase in testosterone at 0.1 and 5 ppb and no changes at 0.5, 50,
or 100 μg/L. Additionally, an increase in estradiol at 5 ppb atrazine was reported, with no changes at
0.1, 0.5, 50, or 100 μg/L. However, a stable testosterone/estradiol ratio was observed [123]. A DOHaD
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study which exposed zebrafish embryos to 0, 0.3, 3, or 30 μg/L atrazine from 1 to 72 hpf did not elicit
significant alterations in ovarian tissue levels of estradiol in adult female zebrafish. However, a
significant increase in ovarian progesterone levels in the 3 and 30 μg/L atrazine treatment groups was
observed [124]. This increase in progesterone is in agreement with previously mentioned rodent
studies [41,44,67]. As previously noted, atrazine exposure was shown to decrease LH and FSH leading
to reproductive dysfunction [46,50]. Furthermore, increases in progesterone may contribute to the
inhibition of the pre-ovulatory surge of LH from the pituitary enhancing reproductive dysfunction. The
results from these and previously mentioned studies show that atrazine elicits an increase in progesterone
levels which can play a role in altered gonad morphology.
4.3. Cellular and Genetic Mechanisms of Reproductive Dysfunction in Anuran and Fish Models
Numerous cellular and genetic mechanisms behind the observed hormonal alterations caused by
atrazine exposure are identified in female and male mammalian in vitro and in vivo studies (discussed in
Sections 2.5 and 3.5). Genetic studies conducted in anuran and fish species have generally focused on
identifying alterations in aromatase (CYP19A1). Aromatase is responsible for catalyzing the conversion
of testosterone to estradiol as well as androstenedione to estrone in the steroidogenic pathway
(Figure 1). Research has focused on this potential mechanism since atrazine was shown not to be an
estrogenic compound (i.e., does not bind to estrogen receptors). Current literature regarding these effects
is under scrutiny as conflicting data are reported. In 2002 and 2010, Hayes et al. [100,102] reported that
atrazine exposure resulted in hermaphroditic, demasculinized, and chemically castrated X. laevis at
concentrations as low as 0.1 and 2.5 μg/L. Hayes hypothesized that the observed morphological
alterations were due to an increase in cyp19a1 expression which would therefore lead to an increase in
estrogen and a decrease in testosterone. In addition, a study exposing zebrafish embryos to 0.3, 3, or
30 μg/L atrazine only through embryogenesis found a significant increase in cyp19a1 in adult female
ovary [114]. Although significant alterations in gene expression were observed, no alterations in ovarian
tissue estradiol were reported. An additional study conducted by Suzawa and Ingraham (2008) which
utilized zebrafish also identified a significant increase in cyp19a1 and an increase in the number of
female fish following atrazine exposure [127]. However, skepticism comes from these results due to the
lack of information provided including the absence of the strain of zebrafish used, sample size, and
mortality rates. Other contrasting studies have not demonstrated that atrazine causes alterations in
cyp19a1 expression in X. laevis and other aquatic species [105,106,112,113,118,123].
5. Epidemiological Studies with Atrazine
Epidemiological studies aiming to address the potential adverse health outcomes associated with
atrazine exposure are gaining interest (Table 4). While occupational exposures typically occur due to
manufacturing or field application, environmental exposures may arise from residual spray drift or most
commonly from the consumption of contaminated drinking water. The aforementioned animal studies
have shown the reproductive toxicity of atrazine in various animal models with varying exposure
periods, treatments, and observational endpoints (Tables 1–3). Despite our knowledge; understanding
the adverse reproductive effects in humans is still under investigation.
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Table 4. Epidemiological studies addressing reproductive alterations associated with atrazine.
Reference
Chevrier et al. [27]

Cragin et al. [130]

Bakke et al. [131]

Ochoa-Acuña et al. [18]
Winchester et al. [132]
Curwin et al. [133]

Barr et al. [17]

Mattix et al. [134]

Munger et al. [135]

Villanova et al. [136]

Results
Quantified levels of atrazine and/or atrazine mercapturate in urine of 5.5% of 579
pregnant females. These levels were associated with fetal growth restriction and small
head circumference. No association with congenital malformations.
Study compared females in Illinois and Vermont and found women who lived in Illinois
had a higher rate of menstrual cycle irregularity, longer follicular phases, and decreased
levels of menstrual cycle biomarker.
Urine samples collected from farm families in Iowa (United States) found higher levels
of urinary atrazine in farmers as compared to controls. High levels of atrazine correlated
to recent field application.
Study revealed higher atrazine levels in drinking water during the third trimester and
entire pregnancy was associated with babies born small for their gestational age.
Elevated levels of pesticide exposure (atrazine) from April to July were associated with
higher rates of birth defects.
Urine samples collected from farm and non-farm families in Iowa (United States) found
higher levels of urinary atrazine in farm families.
Urine samples collected from individuals in Georgia (United States). Atrazine, atrazine
mercapturate, and other atrazine metabolites (DACT, DEA, DIA) were found in urine
samples with DACT being the most prevalent.
Prevalence of abdominal wall defects was higher in Indiana (United States) as compared
to the national rate. Comparison demonstrated a positive correlation between abdominal
wall defects and atrazine exposure.
Iowa study found greater risk of intrauterine growth retardation with higher levels of
atrazine in drinking water.
Atrazine levels in water from the district of Finistère in West Brittany, France, were not
associated with lower birth weight or babies born small for gestational age. Results
suggest association with prematurity.

One of the most recent studies conducted by Chevrier et al., examined the relationship between
adverse birth outcomes and urinary biomarkers of prenatal atrazine exposure. This study was based on
the PELAGIE (Perturbateurs endocriniens: Étude Longitudinale sure les Anomalies de la Grossesse,
l’Infertilité et l’Enfance) cohort in the Brittany region of France. Results from this study found
quantifiable levels of atrazine or atrazine mercapturate in maternal urine samples The presence of
atrazine was associated with fetal growth impairment and small head circumference [27]. An additional
study conducted by Bakke et al., examining Iowa farmers found urinary levels of atrazine mercapturate
were associated with the amount of atrazine applied to crops [131]. A second Iowa study also found
higher levels of urinary atrazine in farm families verses non-farming families [133]. An additional study
by Barr et al., found high levels of atrazine mercapturate and its metabolites (primarily
diaminochlorotriazine (DACT)) present in the urine of turf applicators and non-occupationally exposed
individuals [17]. Although this study had a limited sample size, it concluded that exposure to atrazine
through its application generates higher levels of atrazine mercapturate (or other atrazine metabolites)
compared to low dose exposure caused by the ingestion of food and/or water.
Further studies have also shown a relationship between maternal atrazine exposure (based upon
assumed drinking water levels of atrazine) and an increased risk of babies born small for their gestational
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age (SGA), intrauterine growth retardation (IUGR), and birth defects [18,130–132,134,135]. In contrast,
Villanueva et al., found no association between atrazine concentrations in drinking water and prevalence
of SGA, prematurity, or low birth weight [136]. Observing how atrazine affects the menstrual cycle in
women is also of importance due to atrazine’s ability to alter reproductive hormones (discussed in
Section 2.3). A study conducted by Cragin et al., compared menstrual cycles of women who lived in
Illinois (where atrazine is used extensively) and Vermont (where atrazine is used sparingly) and found
that Illinois women were more likely to report menstrual cycle length irregularity, to have longer
follicular phases, and to have decreased levels of menstrual cycle endocrine biomarkers such as E13G
(major estradiol metabolite) and Pd3G (progesterone metabolite) [130]. The formerly mentioned
epidemiological studies reported various outcomes associated with atrazine exposure. While the majority
of studies have drawn these conclusions with water levels of atrazine ranging from 5.9 to greater than
10 μg/L [18,21,134], further reports showed that atrazine can accumulate up to 154 μg/L [22]. These
studies demonstrate that atrazine exposure can elicit adverse health effects at environmentally relevant
concentrations that are continually above the MCL.
There are many challenges when interpreting epidemiological studies, in regards to the previously
mentioned studies; one particular challenge is that the level of municipal, unfiltered water consumption
among individuals is unknown. Pregnant women and/or families may choose bottled water over tap
water for all or some portions during the studies. Additionally, participants who work outside the home
or travel can also be exposed to different water sources. Furthermore, obtaining accurate assessments of
exposure can be challenging, as there are large seasonal differences in the types, amounts, and frequency
of pesticide application [133]. Of note, is the lack of mention of dietary exposure to atrazine, while these
levels are minimal (0.046–0.286 μg/kg/day), all types of exposure are required for adequate toxicological
assessment [137]. A detailed literature review of atrazine exposure and pregnancy outcomes can be
found in Goodman et al. [138].
6. Conclusions
Overall, the findings from this review demonstrate that atrazine affects the HPG axis. Although
differences are reported dependent on life stage of exposure and dose, common themes do emerge among
the laboratory studies (Figure 2). In summary, female mammalian models have addressed the effects of
atrazine at numerous life stages. Gestational and prenatal studies have demonstrated a significant delay
in VO and a controversial effect on mammary gland epithelium. Adult exposure studies report robust
alterations in reproductive hormones including GnRH, LH, FSH, P4, and PRL. In combination, atrazine
is reported to elicit a prolonged estrous cycle and histological alterations of ovarian tissue including an
increase in atretic follicles. In addition, male mammalian models have begun to be of key importance in
understanding reproductive dysfunction with gestational exposure demonstrating a delay in puberty.
Furthermore, prenatal and adult studies show decreased levels of testosterone and altered testicular
morphology in response to atrazine exposure. In addition, numerous steroidogenic genes and upstream
regulators are altered due to atrazine exposure in both granulosa and Leydig cells. Anuran and fish
models are also providing insight into the reproductive dysfunction and aquatic toxicity of atrazine.
Studies have observed decreases in spawning events and egg production, alterations in hormone levels
and gonad histology, and genetic changes. Epidemiological studies highlight the need for understanding
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the reproductive consequences of atrazine exposure and its impact on rural communities as exposure is
evident in areas where this herbicide is used. Over the past twenty years, studies addressing the adverse
reproductive effects of atrazine have encompassed multiple animal models, treatment levels, and life
stages. While there are still a number of questions that need to be answered surrounding relevancy of the
laboratory findings to human health risks (e.g., comparable exposure doses and continued assessment of
a safe level of exposure), the sustained heavy usage of atrazine in many countries around the globe,
including the United States, results in widespread environmental exposure via drinking water
contamination and signifies the need for continued focus on investigating atrazine’s effects on
reproductive function.
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